Although β 2 -adrenergic receptors (β 2 AR) are expressed on most cell types, mechanisms that establish expression levels and regulate expression by chronic agonist remain unclear. The 3′ UTR of ADRB2 has a conserved 8-nucleotide seed region that we hypothesized is targeted by the let-7 family of miRNAs leading to translational repression. In luciferase assays with transfected cells, luc-β 2 WT3′UTR had decreased expression when cotransfected with let-7f, but a mutated luc-β 2 3′UTR lacking the seed was unaffected by let-7f; a mutated let-7f also had no effect on luc-β 2 WT3′UTR expression. ADRB2 mRNA was in greater abundance in immunoprecipitates of Ago2, a core component of the miRNA-induced silencing complex, when cells were transfected with let-7f, but not with a mutated let-7f, indicating a direct interaction with the silencing mechanism. H292 cells transfected with let-7f caused ∼60% decrease in native β 2 AR expression, but transfection with let-7f-specific locked nucleic acid anti-miRNA increased β 2 AR expression by ∼twofold. We considered that an increase in let-7f leading to greater repression of translation contributes to agonist-promoted down-regulation. Paradoxically, in cells and in lungs from mice treated in vivo, an ∼50% decrease in let-7f occurs during long-term agonist exposure, indicating a counterregulatory event. Consistent with this notion, let-7f locked nucleic acid transfection caused depressed agonist-promoted down-regulation. Thus, let-7f miRNA regulates baseline β 2 AR expression and decreases in let-7f evoked by agonist attenuate down-regulation. This positive feedback loop has not previously been described for a G protein-coupled receptor and its miRNA. Methods to decrease let-7f expression in targeted cells may increase therapeutic responses to β-agonist by increasing β 2 AR expression or minimizing tachyphylaxis.
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desensitization | airways | noncoding RNA | gene regulation G protein-coupled receptors (GPCRs) regulate a large repertoire of physiological functions and their pathways are the most commonly targeted by current therapeutic agents (1) . Most GPCRs undergo agonist-promoted desensitization, defined as a loss of signaling during continuous activation by agonist (2) . Such regulation limits potential deleterious effects from overstimulation and is considered critical to the integration of the multiple signals received by the cell. Early events in agonistpromoted desensitization are phosphorylation of the receptor by G protein-coupled receptor kinases, which promote the binding of β-arrestins that interdict between receptor and G protein, acting to partially uncouple receptor signaling to effectors (2) . For some GPCRs, these events also lead to internalization of the receptor to the intracellular space, where routing back to the cell surface or to degradation pathways take place. With more prolonged exposure to an agonist, a loss of the net complement of cellular receptors is frequently observed, which is termed downregulation. In physiologic settings where stimulation is persistent, down-regulation is readily quantified, such as with elevated catecholamines in heart failure and the down-regulation of cardiac β-adrenergic receptors (βAR) (3, 4) . The down-regulation process can also limit the therapeutic effectiveness of chronic agonist administration, termed tachyphylaxis, as has been demonstrated at the cellular and physiologic levels for β-agonists in the treatment of asthma (5, 6) . The molecular basis for the various components of agonist-promoted GPCR down-regulation, and in particular for that of the prototypic β 2 AR, is not well-defined. Indeed, the mechanisms in play that establish baseline expression of β 2 AR in a given cell, an obvious determinant of the response to endogenous or exogenous agonist, are also not known. Differences (or changes) in transcription (7), mRNA stability (8, 9) , and receptor processing (10, 11) have been described as potential mechanisms that establish baseline β 2 AR expression or agonist-promoted down-regulation. At the level of transcriptional control, multiple transcription factors appear to interact with the promoter and 5′-upstream regions of the intronless ADRB2 gene (12).
Recently, a different level of regulation of many genes has been delineated, which involves RNA-RNA interactions rather than the canonical protein-dependent mechanisms. Indeed, nearly half of all mammalian genes are now predicted to be regulated by small noncoding RNAs (13, 14) . Within the small noncoding RNAs, the miRNAs represent one such group with regulatory potential. MicroRNAs are small, single-stranded molecules approximately 21 nucleotides in length. They have the capacity to modulate protein expression levels in response to changing environmental stimuli by controlling protein synthesis in a highly specific spatiotemporal pattern (15, 16) . This type of miRNA:mRNA interaction, usually occurring at the 3′ UTR, leads to translational repression, likely through steric hindrance of RNA polymerase actions (17, 18) . It has been proposed that this mode of action provides cells the capacity to regulate protein expression levels in a controlled manner yet maintain a full complement of mRNA for a given gene (19) . Here we define a unique mechanism by a member of the let-7 family of miRNAs that sets the baseline level of expression of β 2 AR, and is regulated by agonist leading to a counteraction to down-regulation. source) deriving structural and minimum free energy (mfe) binding predictions. Fig. 1A shows the predicted let-7f stem loop structure and a mfe of −19.9 kcal/mol associated with the interaction between ADRB2 mRNA and let-7f. This β 2 AR sequence was found to be fully conserved across multiple species, with the let-7f binding site located at virtually the same location within the 3′ UTR (Fig. 1B) . To test these prediction models that the let-7 family of miRNAs can functionally interact with the 3′ UTR of ADRB2, HEK293 cells were used for transfecting β 2 AR-3′UTR-based constructs. HEK293 were transfected with a construct consisting of firefly luciferase followed by the 3′ UTR of ADRB2 (pGL3-β 2 WT3′UTR) and a mutated 3′ UTR (mfe = −15.8 kcal/ mol) lacking the predicted let-7f binding domain (pGL3-β 2 Mut3′ UTR), as well as WT or a mutated let-7f (mfe = −12.6 kcal/mol). The characteristics of these mutated constructs are shown in Fig. 2A . As shown in Fig. 2B , luciferase activity decreased with cotransfection of WT let-7f in a dose-dependent fashion, consistent with let-7f-mediated translational repression. In contrast, let7f had no effect on firefly luciferase expression when the mutated 3′ UTR construct lacking the predicted let-7f binding site was transfected (Fig. 2C ). In addition, the mutated let-7f that lacked the seed region for the ADRB2 3′UTR interaction (let-7f-mut) had no effect when coexpressed with the pGL3-β 2 WT3′UTR construct (Fig. 2C ). These studies with WT and mutated ADRB2 3′ UTR, and WT and mutated let-7f, indicate that the observed effects of let-7f on ADRB2 3′ UTR-based repression are not a result of offtarget or nonspecific interactions that might occur because of miRNA transfection. Taken together, these studies point toward an interaction between let-7f and a specific region of the ADRB2 3′ UTR that acts to repress expression. Let-7f Promoted Interaction of ADRB2 mRNA and the RNA Silencing
Results
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Complex Component Ago2. Most miRNAs are transcribed as primiRNA. These molecules have a characteristic stem-loop structure and are the target of cleavage by the microprocessor complex consisting of Drosha and DGCR8 (20) . The resulting 60 to 70 nucleotide pre-miRNA is then exported to the cytoplasm by the Ran-GTP-dependent nuclear receptor Exportin-5, where it is further processed by the Rnase III enzyme Dicer into ∼21 nucleotide miRNA:miRNA* duplexes. Finally, one strand of this duplex (termed guide miRNA) is assembled into a ribonucleoprotein known as miRNA-induced silencing complex (miRISC); the other strand (termed "passenger strand") is degraded. The core component of miRISC is Ago2, a member of the Argonaute endonuclease family, which binds the remaining guide strand to silence target mRNAs (21) . If β 2 AR is regulated by the proposed miRNA pathway, then overexpression of let-7f should lead to an increase in Ago2-bound ADRB2 mRNA. To test this, H292 (a human airway epithelial cell line that natively express β 2 AR) extracts were immunoprecipitated with an Ago2 antibody, and the immunoprecipitates probed quantitatively for ADRB2 mRNA by real-time RT-PCR. The specificity of the antibody and the immunoprecipitation method is shown in Fig. 3A , using Western blotting of the immunoprecipitates where the precipitating antibody was either the Ago2 antibody or IgG. Control (mock-transfected), let-7f-, and let-7f-mut-transfected cells were studied. Immunoprecipitated Ago2 protein was observed only with Ago2 antibody and not with IgG, and Ago2 was expressed at comparable levels under the conditions of all three transfections. When these complexes were then subjected to ADRB2-specific real-time RT-PCR, marked differences in ADRB2 mRNA content were observed (Fig. 3B) . In these cells, a modest enrichment of ADRB2 mRNA was observed in Ago2 vs. IgG immunoprecipitates in the nontransfected cells.
With cotransfection of let-7f, a significant increase in ADRB2 mRNA was detected in Ago2 immunoprecipitates. In contrast, extracts from cells transfected with the let-7f-mut construct showed no enrichment of ADRB2 mRNA from Ago2 immunoprecipitates over that of the nontransfected controls.
Let-7f Regulates Endogenous β 2 AR Expression and Limits AgonistPromoted Down-Regulation. The above studies indicate a specific interaction between let-7f miRNA and the 3′ UTR of ADRB2, which results in repression of a reporter gene. In addition, the studies indicate that there is a direct correlation between the amount of transfected let-7f and the extent of expression. The enrichment of ADRB2 mRNA from Ago2 immunoprecipitates from cells transfected with let-7f further validates a miRNAbased effect of let-7 for β 2 AR expression. We next assessed whether let-7 regulates baseline expression of β 2 AR protein natively expressed on H292 cells by increasing let-7f expression and functional let-7f knock-downs. β 2 AR protein expression on cell membranes was determined by quantitative 125 I-cyanopindolol ( 125 I-CYP) radioligand binding. Transfection of let-7f resulted in an ∼60% decrease in β 2 AR expression (Fig. 4A) . No change in expression was found when let-7f-mut was transfected. Endogenous let-7f activity was inhibited by transfection of a let-7f-specific locked nucleic acid (LNA) anti-miRNA. As shown in Fig. 4A , let-7f LNA increased native β 2 AR expression by ∼two-fold over control cells. These studies confirm that native β 2 AR protein expression is specifically modulated by let-7, with a range of influence amounting to fourfold (∼50 to ∼200 fmol/mg). We hypothesized that let-7f might be up-regulated with agonist exposure, and thus the increased repression of translation would be a component of the agonist-promoted down-regulation process. However, we found a 33 ± 7% decrease in let-7f expression in H292 cells after 12 h of exposure to 10 μM of the β 2 AR agonist fenoterol (P < 0.05, n = 7). Using pharmacologically relevant doses of fenoterol delivered for 7 d to mice, we noted a dosedependent decrease of up to 50% in lung let-7f expression compared with lungs from sham-treated mice (Fig. 4B) . Given that these conditions readily evoke a loss of β 2 AR expression (Fig. 5) (22, 23) , we then considered that agonist-promoted decreases in let-7f are a mechanism to limit the extent of agonistpromoted down-regulation. Thus, the net effect on β 2 AR expression from prolonged agonist exposure includes a counterregulatory loss of miRNA-mediated translational repression. To further examine this effect, H292 cells were transfected with let7f LNA or a scrambled LNA control in the absence or presence of 12-h agonist exposure. We expected that the effect of lowering let-7f by agonist exposure and also decreasing the effect of the remaining let-7f by LNA would lead to decreased down-regulation, as translational repression would be minimized by the two mechanisms. As shown in Fig. 5 , this was indeed the case, with agonist-promoted down-regulation amounting to ∼91% in control cells and agonist-promoted down-regulation in the face of let-7 LNA transfection being ∼74%.
Discussion
GPCRs serve as critical elements in the maintenance of homeostasis at the cell, organ, and organism levels under normal physiologic states and during pathophysiologic conditions. These receptors are targets for pharmacologic therapy with receptor agonists and antagonists for a wide range of diseases, and have also been implicated in aberrant responses contributing to disease. A key aspect of signaling by most GPCRs is the capacity to adapt to a changing environment. This plasticity is a necessary attribute because the influences that impact a given state are highly dynamic, thus requiring receptors to adjust signaling along timeframes ranging from seconds to days. Of particular interest have been the mechanisms by which a cell regulates the level of receptor expression and how expression is affected by chronic agonist exposure. In regards to the former, "basal" receptor expression is considered a major determinant of the response to endogenously generated or exogenously administered agonist (24) . With prolonged agonist exposure, many GPCRs display a decrease in expression, which is termed down-regulation, and is one component of tachyphylaxis to administered agonists; downregulation from elevated levels of endogenous agonist is also apparent (3, 4) . For the prototypic β 2 AR, these adaptive responses, such as rapid phosphorylation by G protein-coupled receptor kinases, and many of the mechanisms that are apparent over longer time courses have been documented (2, (25) (26) (27) . The mechanisms responsible for β 2 AR down-regulation have been shown to occur at the level of transcription (7), mRNA stability (8, 9) , and protein degradation (10, 11) . Here we show an additional component, translational repression by let-7f, which has a two-pronged effect on receptor expression (Fig. 6 ). Basal levels of β 2 AR expression appear to be effected by this mechanism, and indeed let-7-dependent regulation resulted in protein expression levels that span at least a fourfold range. Of note, measured β 2 AR expression varies between individuals by about this same extent in many tissues, such as heart (28), skeletal muscle (29) , peripheral lung (30), lymphocytes (30) , and airway epithelial cells (5) , supporting the notion that this variation in expression is within the physiologic range. We do not claim, however, that this let-7 mechanism is the only means by which basal levels of β 2 AR are set, but rather it is one mechanism that results in changes within the known range in relevant tissues. Interestingly, let-7f binding sites are also predicted in the 3′ UTRs of the β 1 AR and β 3 AR subtypes (704-710 and 521-527 nucleotides from the stop codons, respectively) but are not found in genes for the three α 1 AR subtypes or the three α 2 AR subtypes. This finding suggests that the let-7 mechanism defined in the present report may be a βAR-specific mechanism within the adrenergic receptor family.
An unexpected finding was the effect of prolonged agonist exposure on let-7f expression. Given the efficient control of β 2 AR expression exhibited by let-7f, we assumed that it participated in agonist-mediated down-regulation by enhanced expression and thus increased gene silencing. However, we found that let-7f expression was decreased by prolonged agonist exposure. Given that the net effect of such exposure is decreased β 2 AR expression, the decrease in let-7f, which causes an increase in β 2 AR expression, appears to be a counterregulatory event that attenuates downregulation (Fig. 6) . Several reports indicate that GPCR activation can alter miRNA expression, which has been linked to altered expression of other proteins (31) . Furthermore, forskolin treatment of cardiomyocytes has been shown to increase miR-1 miRNA expression (32) . However, we are unaware of a feedback loop as reported here for the β 2 AR being previously shown between any GPCR and miRNAs that regulate its expression. In the present report, activated β 2 AR leading to decreased let-7 would be considered a positive feedback loop, in that decreased let-7 diminishes ADRB2 translational repression and thus shifts the equilibrium toward an increase in β 2 AR expression. To our knowledge, no positive feedback loops regulating human β 2 AR expression by any mechanism have been reported. The previously characterized regulatory events that accompany agonist activation result in a loss of expression or function. It is not entirely unexpected, however, that "buffering" mechanisms would also be present, essentially providing additional control nodes to moderate negative feedback. Finally, we note that only two other groups of miRNAs, represented by miR-15 and miR-30, have predicted binding sites within the 3′ UTR of the β 2 AR (Fig. S1) . The functional effects of these miRNAs will require additional study.
In summary, we have shown here that translational repression imposed by the binding of let-7f to the 3′ UTR of the β 2 AR regulates baseline expression. Such regulation can be demonstrated in transfected cells and natively expressing cells, and is highly specific because mutations of the 3′ UTR or let-7f abolish the effect. The range of control over β 2 AR expression is within the physiological range. In addition, agonist activation of the β 2 AR decreases let-7f expression, leading to an attenuation of agonist-promoted down-regulation. Taken together, these stud- Fig. 5 . Effects of let-7f miRNA on agonist-promoted β 2 AR down-regulation. H292 cells were transfected with scr let-7f LNA (representing the control condition) or let-7f LNA to depress let-7f effects. Cells were treated with carrier (0.1 mM ascorbic acid, control) or carrier with 10 μM fenoterol for 12 h, washed, and 125 I-CYP binding performed to quantitate β 2 AR expression. *Down-regulation less than scr control, P < 0.05, n = 3.
ies suggest that genetic or pharmacologic means of modulating let-7 expression in target tissues, such as heart or lung, may improve therapeutic outcome by increasing baseline β 2 AR expression or attenuating tachyphylaxis.
Methods
Constructs and Luciferase. To generate the ∼600-bp β 2 3′ UTR, the following PCR primers were used to amplify this fragment from human genomic DNA: forward primer: 5′-AGCAGTTTTTCTACTTTTTA AAGAC-3′ and reverse primer: 5′-AGGCAACAGCACTCCAGTCAAG-3′. This PCR product was subsequently cloned into the firefly luciferase pGL3-Control vector downstream of the luciferase ORF at the XbaI site to generate pGL3-β 2 WT3′UTR. Orientation and sequence accuracy were confirmed by sequencing. To generate the β 2 mut3′UTR, site-directed mutagenesis (Strategene) was used to mutate the first two nucleotides (CU to AA) within the let-7 seed region of β 2 WT3′UTR. The let-7f-mut miRNA containing mutations within its seed region was obtained from Invitrogen. For luciferase assays, HEK293 cells were seeded in 96-well plates. Transfections used lipofectamine 2000 (Invitrogen) with pGL3-β 2 WT3′UTR, pGL3-β 2 mut3′UTR, let-7f, or let-7f-mut, and renilla luciferase (pRL-SV40), which was used as a transfection control. Luciferase activity was measured using the dual-luciferase reporter assay (Promega). Forty-eight hours after transfection, cells were lysed and luciferase activities were measured on a Victor 3 Multilabel Counter (Perkin-Elmer). Data are reported as the firefly:renilla luciferase activity ratios.
Immunoprecipitation. Immunoprecipitation studies were performed on H292 cells (ATCC) transfected with let-7f or a scrambled control, using a modification of previously described methods (33) . Briefly, 1 mg of whole-cell lysate was precleared with protein A/G agarose and then incubated with 1:50 Ago2 antibody (Cell Signaling) or control IgG (Santa Cruz) for 1 h at 4°C. After addition of 50 μL of protein G agarose, the lysates were incubated for 12 h at 4°C. Agarose beads were washed by serial centrifugation with lysis buffer, high salt, and then low-salt buffer. RNA was extracted with TRIzol (Invitrogen), precipitated with isopropanol in the presence of glycogen to aid in pellet recovery, and treated with DNase I (Applied Biosystems). Complementary DNA was generated using SuperScript III reverse transcriptase and quantitated by real-time PCR as described elsewhere (34) . The 18s rRNA was used for normalization. Western blots were performed on the immunoprecipitated material, as previously described (35, 36) , with the following modifications: 25 μL of gel-loading buffer was directly loaded on the agarose pellet and the protein was denatured for 3 min at 100°C. Membranes were blotted with antihuman Ago2 (Wako) at a titer of 1:200. The ECL Advanced Western Blotting kit (GE Healthcare) was used for detection and images were acquired using the Fuji LAS-3000 camera (Fujifilm Medical Systems) and quantitated using the associated software. bound radioligand separated from free by vacuum filtration over glass-fiber filters (Whatman), which were counted in a γ counter. Nonspecific binding was determined by coincubations with 10 μM propranolol, and all tubes contained 100 μM GTP. For receptor down-regulation studies, H292 cells were transfected with either let-7f LNA or an LNA scrambled control; after 48 h, cells were treated with the β 2 AR-specific full-agonist fenoterol for an additional 12 h followed by washing three times with cold PBS and 125 I-CYP binding, as described above. Results are expressed as femtomole per milligram or as a percentage of the expression of cells under a control condition.
Mouse Studies. The mouse studies were approved by the Institutional Animal Care and Use Committee at the University of Maryland School of Medicine. Twelve-to 18-wk-old FVB mice (Taconics) were administered intraperitoneal injections of fenoterol at 5 μg/d or 15 μg/d for 7 consecutive days; controls were administered saline. Following drug treatment, lungs were harvested and RNA extracted using TRIzol reagent. For detecting let-7f levels, real-time PCR as described above was used to determine expression levels with U6 snRNA used as an internal control.
MicroRNA Target Prediction and Sequence Alignment. Multiple species alignment of the β 2 AR 3′ UTR was performed using the University of California Santa Cruz Genome Browser (http://genome.ucsc.edu) (38) . To identify potential miRNA binding sites within the 3′ UTR of β 2 AR, the following bioinformatic databases were used: TargetScan (http://www.targetscan.org) (39), the microRNA.org resource (http://www.microrna.org) (40) , MicroCosm (http://www.ebi.ac.uk/enright-srv/microcosm) (41), and PicTar (http://pictar. mdc-berlin.de) (42) . MicroRNA-mRNA free energies were determined using RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid) (43) .
Data Analysis and Statistics. All statistical calculations were performed using Prism (GraphPad). Comparisons were by two-way paired or unpaired t tests, with P < 0.05 considered significant. Comparisons among multiple conditions were performed by ANOVA followed by post hoc t tests. Data are expressed as mean ± SEM of n experiments.
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